Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines
Phase 3negativePelacarsenNegative
AI Analysis
Summary
Pelacarsen, a Novartis-Ionis cardiovascular drug, failed to demonstrate heart health protection despite effectively lowering Lp(a) protein levels in a large clinical trial, raising questions about the viability of this emerging drug class.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
Failed to protect heart health despite lowering Lp(a) protein particle levels in large clinical trial
Importance:8/10
Sentiment:
-0.85
Phase 3 failurecardiovascularLp(a)clinical trialdrug development
Read the original article
Published by BioPharma Dive on September 5, 2026 4:51 PM